Pharmaceuticals News and Research

RSS

Researchers obtain first detailed and complete picture of PRC2 protein

The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).

18 Sep 2012

MediSapiens launches unified cloud computing application for personalized genomics

MediSapiens launches first-in-kind fully integrated and unified cloud computing application that harnesses the power of Big Data and enables knowledge-based drug discovery and repositioning for personalized genomics.

17 Sep 2012

Wockhardt receives FDA marketing approval for Lansoprazole

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, which is used in treatment of peptic ulcers. Lansoprazole is the generic name for the brand Prevacid, marketed in the United States by Takeda. Wockhardt is launching the product immediately.

17 Sep 2012

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.

17 Sep 2012

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

17 Sep 2012

Researchers investigate African plants effective in treating snakebite

A PhD student at the University of Copenhagen has drawn on nature's own pharmacy to help improve the treatment of snakebites in Africa.

17 Sep 2012

World Bank, Bangladeshi government sign multi-donor trust fund agreement for country's health sector

"On Wednesday, the World Bank and the Bangladeshi government signed a Multi-Donor Trust Fund Grant Agreement" under which "$280 million coming from the United States, Australia, the United Kingdom, and Sweden will go to the Bangladesh Health Sector Development Program, which aims to improve the health status of people in Bangladesh, particularly women, children and the marginalized," the Devex "Development Newswire" reports.

15 Sep 2012

First annual Golden Goose Awards honor eight scientists

Eight scientists, including four Nobel Prize winners, will be honored today with the first annual Golden Goose Awards, celebrating researchers whose seemingly odd or obscure federally funded research turned out to have a significant impact on society. The awardees will be honored at a ceremony on Capitol Hill, where they will receive their awards from a bipartisan group of Members of Congress.

15 Sep 2012

Levitation can improve drug development process

It's not a magic trick and it's not sleight of hand - scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects.

14 Sep 2012

Trigeminal Nerve Stimulation: an interview with Dr Leon Ekchian, President and CEO of NeuroSigma

Trigeminal Nerve Stimulation (TNS) is a novel medical treatment in which mild electrical signals stimulate branches of the trigeminal nerve in order to change the activity of targeted brain regions. The trigeminal nerve is the largest cranial nerve, and provides sensation to the face and head. Because it is a large sensory nerve, the trigeminal offers a high-bandwidth pathway for electrical signals to enter the brain. The brain areas targeted by TNS are known to play key roles in seizures, mood, and attention.

14 Sep 2012

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announce the availability of a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health.

14 Sep 2012

Viewpoints: Medicaid's role in lowering uninsured rate; Need to protect physicians 'compelled by conscience' to provide abortions

The number of Americans who lack health insurance declined last year, the first drop since 2007. This is, in large part, the result of the health care reform law and better coverage under public programs like Medicaid. This also shows why repealing the health care law or revamping and shrinking Medicaid, as many Republicans want to do, would be disastrous moves.

14 Sep 2012

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

14 Sep 2012

Patheon third quarter revenues increase to $203.7 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today fiscal 2012 third quarter and nine month results.

13 Sep 2012

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.

13 Sep 2012

Pathogens and Global Health highlights current debate on counterfeit medicine

The latest issue of Pathogens and Global Health highlights the current debate surrounding the under-investigated, and politically sensitive, issue of counterfeit medicine. Issue 106.2 includes an interview with Dr Paul Newton, Head of the Laos arm of the Wellcome Trust's Major Overseas Programmes, and a number of articles highlighting the technological innovations and field initiatives that are challenging this threat to global health.

13 Sep 2012

Positive results from Edison’s EPI-743 phase 2A study on Leigh Syndrome

Edison Pharmaceuticals today announced positive results of a recently completed phase 2A study entitled, "Prospective Open Label Study of EPI-743 in Children with Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)."

13 Sep 2012

Synthetic biology pioneer wins 2012 Heinz Award

Jay Keasling, a leading authority and pioneer on synthetic biology who has engineered microbial "factories" to manufacture an affordable version of a frontline antimalarial drug and biofuel substitutes for gasoline, diesel and jet fuel, has won a 2012 Heinz Award, which is presented by the Heinz Family Foundation and carries with it a cash prize of $250,000.

13 Sep 2012

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Glenmark Pharmaceuticals S.A. (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited (GPL), announced today that GBR 500 has entered Phase II clinical development.

13 Sep 2012

Pharmaceuticals News and Research

Researchers obtain first detailed and complete picture of PRC2 protein

MediSapiens launches unified cloud computing application for personalized genomics

Wockhardt receives FDA marketing approval for Lansoprazole

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Researchers investigate African plants effective in treating snakebite

World Bank, Bangladeshi government sign multi-donor trust fund agreement for country's health sector

First annual Golden Goose Awards honor eight scientists

Levitation can improve drug development process

Trigeminal Nerve Stimulation: an interview with Dr Leon Ekchian, President and CEO of NeuroSigma

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Viewpoints: Medicaid's role in lowering uninsured rate; Need to protect physicians 'compelled by conscience' to provide abortions

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

Patheon third quarter revenues increase to $203.7 million

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

Pathogens and Global Health highlights current debate on counterfeit medicine

Positive results from Edison’s EPI-743 phase 2A study on Leigh Syndrome

Synthetic biology pioneer wins 2012 Heinz Award

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence